Pfizer Study Shows COVID-19 Vaccination Reduces Symptoms, Improves Work Productivity
There is presently no federal law in the US that guarantees paid time off for employees, and many are not even eligible for unpaid time off.
A 2020 U.S. Bureau of Labour Statistics report states that 78% of employees have access to paid sick leave. This indicates that when illness strikes, nearly one in four workers could face financial difficulties.
COVID-19 can have a substantial negative impact on people’s health and well-being, which lowers their quality of life in relation to their health. Fever, coughing, and exhaustion are common signs of infection that hinder productivity and make it more difficult to work and do everyday duties.
The World Health Organisation states that the COVID-19 immunisation, in particular the bivalent BNT162b2 formulation, has demonstrated “very high efficacy against severe disease and moderate efficacy against symptomatic SARS-CoV-2 infection.”
In a research released in October, Manuela Di Fusco, senior director of Health Economics and Outcomes Research at Pfizer, and her team examined how the company’s BA.4/5 BNT162b2 COVID-19 vaccine affected symptoms, productivity at work, and health-related quality of life (HRQoL).
A total of 643 participants were enrolled in the study: 316 of them were vaccinated and 327 of them were not. Those who had never gotten the COVID-19 vaccine as well as those whose dose had expired more than a year ago were included in the unvaccinated cohort. The participants’ average age was 46.5 years, and 25.7% of them had one or more comorbid conditions. This study focused on adults with a positive test result and at least one acute COVID-19 symptom. Participants were people who were tested for SARS-CoV-2 at CVS Health test sites. Participants provided patient-reported outcomes.
Online questionnaires were used in the trial to gather baseline data on participant demographics, comorbidities, history of infections, and COVID-19 immunisation. Information on modifications in immunisation and infection status, as well as COVID-19 antiviral therapy, was also supplied by the participants. Using established criteria, the study assessed participants’ symptoms, HRQoL, weariness, job productivity, and impairment from activities at various periods during a four-week period.
The study’s conclusions showed that the group that received the vaccination experienced a reduction in acute symptoms, especially the systemic and respiratory symptoms that are frequently connected to COVID-19. Furthermore, the vaccinated group outperformed the unvaccinated group in work performance, even though all subjects had some negative impacts on their total HRQoL. Those who had got the vaccination showed reduced absence rates and fewer lost work hours as proof of this.
The researchers found that compared to the unvaccinated group, the vaccinated group exhibited fewer and milder symptoms. Moreover, the increased efficiency with which they perform their jobs highlights the positive impact of the COVID-19 vaccination on people’s ability to effectively carry out their daily responsibilities.